Covalent Albumin Microparticles as an Adjuvant for Production of Mucosal Vaccines against Hepatitis B

详细信息    查看全文

• 作者：Danielly L. A. Sitta ; Marcos R. Guilherme ; Francielle P. Garcia ; Thelma S. P. Cellet ; Celso V. Nakamura ; Edvani C. Muniz ; Adley F. Rubira
• 刊名：Biomacromolecules
• 出版年：2013
• 出版时间：September 9, 2013
• 年：2013
• 卷：14
• 期：9
• 页码：3231-3237
• 全文大小：457K
• 年卷期：v.14,no.9(September 9, 2013)
• ISSN：1526-4602

文摘

Covalently modified albumin (BSA) microparticles were developed for potential use as an adjuvant in mucosal vaccines against hepatitis B. To synthesize consistent protein particles, a covalent approach was proposed to modify BSA. Our strategy was to bond maleic anhydride (MA) molecules to BSA structure by nucleophilic reaction for further radical cross-linking/polymerization reaction with N鈥?N鈥?i>-dimethylacrylamide (DMAAm). The presence of poly(N鈥?N鈥?i>-dimethylacrylamide) in the protein network enables the microparticles to show well-defined, homogeneous forms. Cytotoxicity tests showed that the cytotoxic concentration for 50% of VERO cells (CC₅₀) was 216.25 卤 5.30 渭g mL^鈥? in 72 h of incubation. The obtained CC₅₀ value is relatively low for an incubation time of 72 h, suggesting an acceptable biocompatibility. Assay of total protein showed that the encapsulation efficiency of the microparticles with hepatitis B surface antigen (HBsAg) was 77.7 卤 0.2%. For the reference sample, which was incubated without HBsAg, the quantity of protein was below the limit of detection.